| ME THODS
This is a prospective observational investigation that included transplant recipients who underwent lung transplant surgery between February 2014 and February 2017 and were agreeable to participation in this investigation while awaiting lung transplant.
Information about the patient's self-report of alcohol use was obtained from the transplant social worker's interview with the patient, which was a part of the lung transplant evaluation process.
Just prior to lung transplant surgery, the patient was administered the AUDIT questionnaire, assessing for alcohol misuse. Whole blood, serum, and urine samples were collected from lung transplant recipients at the time of transplantation to assess for alcohol use utilizing objective alcohol biomarkers. Demographic, medical history, and post-lung transplant outcomes were collected from the recipient's medical records. The Institutional Review Board of Loyola University Chicago Health Science Division approved this study (LU204490).
| Alcohol biomarkers
Values for clinically utilized alcohol biomarkers such as AST, ALT, and MCV were obtained from recipient charts or blood was sent to Quest laboratories (Quest Diagnostics, Chantilly, VA, USA) for measurement, if these values were not clinically available. Whole blood, serum, and urine were collected on recipients at the time of their lung transplant surgery for measurement of direct and indirect alcohol biomarkers including whole blood for PEth, serum for percent carbohydrate-deficient transferrin (%CDT), an indirect alcohol biomarker, and urine for EtG. Dried blood spots were created with 40 μL of vortexed whole blood which were then sent to the United States Drug Testing Laboratories (USDTL, Des Plaines, IL) for analysis of PEth by liquid chromatography-mass spectrometry (LC-MS). LC-MS was conducted using a previously published method. 19 Frozen aliquoted serum was sent to Quest laboratories (Quest Diagnostics, Chantilly, VA) to determine serum levels of %CDT. Serum analysis was conducted in a manner similar to that proposed by Schellenberg et al 20 using rate-nephelometric determination after anion-exchange separation. Finally, urine was collected for analysis of EtG also sent to Quest laboratories for analysis via immunoassay.
| Alcohol use quantification
Alcohol use in patients with advanced lung disease was quantified using self-report during a pretransplant interview with the lung transplant social worker. The AUDIT was utilized in addition to selfreport to identify any alcohol misuse. To improve the accuracy of the questionnaire, it was administered after the patient was called into transplant; therefore, there was no possibility that their answers to the AUDIT could influence whether or not they received a lung transplant. Alcohol misuse was defined according to the Centers for Disease Control (CDC) definition for excessive alcohol use: >1 drink per day on average or ≥4 drinks consumed on one occasion in 1 month for women; >2 drinks per day on average or ≥5 drinks consumed on one occasion in 1 month for men. 21 An AUDIT score >5 in females and >8 in males indicates alcohol misuse. 14, 22 Recent alcohol use included a positive direct alcohol biomarker, either and/or both a positive PEth and/or urine EtG as evidence of recent alcohol use prior to transplant surgery. PEth has a reported sensitivity for recent alcohol use of 99% with diagnostic specificity of nearly 100%, whereas urine EtG has a sensitivity of nearly 100% with specificity of 94%. 12, 13, 15 EtG can detect recent alcohol use in the urine for approximately 2-4 days after imbibing alcohol. 23 PEth is detectable in the blood 3-12 days after a single ingestion of an alcoholic drink, with a reported detection window of 2-3 weeks with larger quantities of alcohol.
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| Statistical analysis
Patient demographic and clinical characteristics were presented as means and standard deviations, medians and interquartile ranges, or counts and percentages as appropriate. Serum cytokines were compared for patients with and without positive biomarkers for alcohol use, and differences were assessed with Wilcoxon rank-sum tests. Similarly, Wilcoxon rank-sum tests were used to compare outcomes including days at the hospital, in the ICU, and extubated for those with and without evidence of recent alcohol use as well as with AUDIT ≥3 vs <3. The proportions experiencing graft dysfunction or death by alcohol use were compared using Fisher's exact test.
| RE SULTS
During the study period, 139 lung transplants occurred. Nineteen declined participation and 34 were never approached for consent.
Therefore, 86 patients with advanced lung disease agreed to participate and were included in this investigation. Their demographics, clinical diagnosis and information, and AUDIT scores are contained in Table 1 . The majority of the participants were middle-aged (mean age 55, SD = 13), male (59%) and Caucasian. Common pulmonary diagnoses included COPD (34%), idiopathic pulmonary fibrosis (20%), idiopathic interstitial pneumonia (16%), and cystic fibrosis (12%). The alcohol self-report to the transplant social worker showed that 54%
had a history of alcohol use and 34% were currently using alcohol.
The interview with the social worker took place mean 6.5 (IQR 2.9- Information about the AUDIT scores in patients with advanced lung disease is contained in Figure 1 . Nearly two-thirds of the patients had an AUDIT score of 0 at the time of their lung transplant, 25% had scores 1-2, and 13% had a score ≥3. Only 1 individual had an AUDIT score indicating alcohol misuse (>8), with a score of 12.
The AUDIT questions which were most often answered positively History of use reported to social worker, n (%) (n = 83)
(54)
Current use reported to social worker, n (%)(n = 83) 28 (34) Months from SW interview to transplant, median (IQR) 6.5 (2.9-12.8)
Positive direct alcohol biomarkers, n (%) (n = 77) 8 (10) Urine EtG (n = 73) 4 (6) PEth (n = 50) 5 (10) Missing values: n = 9 alcohol biomarkers, n = 3 social worker history/current use. ETG, ethylglucuronide; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; PEth, phosphatidylethanol; SD, standard deviation.
F I G U R E 1 Alcohol Use Disorders Identification Test (AUDIT) scores at lung transplant in a cohort of patients with advanced lung disease. Figure 1A shows the percentage of patients in the cohort and their corresponding AUDIT scores. Only 1 of 86 patients scored AUDIT positive for alcohol misuse. Figure 1B assesses which questions (Q) were answered affirmatively by the patients with advanced lung disease. Q 1-3 cover the domain measuring frequency of alcohol consumption, Q 4-6 measure alcohol dependence, and Q 7-10 measure alcoholrelated problems. Those with "recent alcohol use" as evidenced by positive direct alcohol biomarkers, EtG and/or PEth, were grouped together and compared to the group with no recent alcohol use (negative EtG and/or PEth). There were 8 recipients in the "recent alcohol group," as 3 recipients were positive by urine EtG only as no PEth was collected, 2 recipients who were positive by PEth only, as no urine was collected, and 1 was positive by both PEth and urine EtG. Two recipients were positive by PEth only with a negative urine EtG. The window of detectability for PEth is 2-3 weeks, whereas urine EtG is only 2-3 days; therefore, it is likely that those 2 recipients had a drink greater than 4 days prior to transplant, but within 2-3 weeks of transplant. 13, 15 There were 9 patients where neither EtG or PEth was collected due to emergent transplantation or logistical issues, and therefore, these patients were excluded from this part of the analysis. Demographics, clinical information, and alcohol biomarkers for each of the cohorts are contained in Table 2 . There were no signifi- following lung transplant (P = .028). These patients spent 3 times
, and alcohol biomarkers. Alcohol self-report to the transplant social was grouped into 5 alcohol use subcategories. Figure 2A shows the number of patients with AUDIT score <3 compared to AUDIT score ≥3 (n = 83) within each alcohol use subcategory. Figure 2B Table 4 . Post-lung transplant complications in those with recent alcohol use were numerous and did not show a specific trend, although complications that were present in more than 1 patient, and that could prolong LOS included atrial arrhythmia, acute kidney injury, and acute cellular rejection (Table 4) .
| D ISCUSS I ON
Alcohol use amongst people with advanced lung disease has sparsely been investigated previously, and therefore, knowledge about the drinking habits in this patient population is limited.
In this novel investigation, we found that the majority of peo- Missing values: n = 9 alcohol biomarkers, n = 7 CDT, n = 2 AST/ALT. ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUDIT, alcohol use disorders identification test; BMI, body mass index; CDT, carbohydrate-deficient transferrin; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; ETG, ethylglucuronide; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; LAS, lung allocation score; MCV, mean corpuscular volume; PEth, phosphatidylethanol; SD, standard deviation. It is reassuring to note that most of the cohort is abstaining or has very little use of alcohol while awaiting lung transplant. At out center, the patients pursing lung transplant are counseled to limit alcohol intake in order to optimize their health and prepare to abstain after transplant, given the many potential drug interactions.
TA B L E 2
We found a similar rate of alcohol consumption in patients with advanced lung disease pursing lung transplant (34%) as a previous investigation, which found alcohol use rates of 25% and 33% in their non-CF and CF patient cohorts, respectively. 9 In the non-CF lung transplant group, mean number of drinks per week was 5.6, with only 2.0 drinks per week recorded in the CF lung transplant group. These rates of alcohol use were similar to what was observed in heart transplant candidates and higher than liver transplant candidates (6%). 24, 25 The lower rate in liver transplantation is likely due to the strongly encouraged or requirement of alcohol abstinence in liver transplantation.
The gold standard for quantifying alcohol use is by patient selfreport. 11 We did find that amongst those lung transplant candidates with positive alcohol biomarkers, the AUDIT score was more likely to be increased. The AUDIT is a 10-question survey that is easily ad- morbidities. 10 Blood alcohol content is metabolized within hours of alcohol ingestion and is not a good screen for alcohol use in the clinic. 10 EtG, which is present in the urine for approximately 2-4 days and has a very high sensitivity and specificity for recent alcohol use, is a good clinically available screening test. 23 The direct alcohol biomarker, PEth, which is also extremely sensitive and specific for recent alcohol use and is detected in the blood 3-12 days after a single ingestion of an alcoholic drink, is not yet clinically available. PEth can be detected up to 3 weeks when large quantities of alcohol are imbibed. 17 In liver transplantation, monitoring wait list candidates for alcohol use is essential given the devastating effects that alcohol use can have on the liver post-transplant. A recent investigation into various alcohol use self-report tools and alcohol biomarkers revealed that utilization of the short form AUDIT (AUDIT-c) along with urine EtG was most useful for detecting alcohol consumption in these potential transplant candidates. 25 In our investigation, we utilized positive EtG or PEth to represent recent drinking as the sensitivity and specificities of these 2 tests to detect alcohol use in the days prior to transplant surgery are superior at detecting low to moderate alcohol use. 10, 16, 18 The subgroup of patients with advanced lung disease who self- The cost of hospitalization following lung transplant is estimated at $566 900 for bilateral transplant. 31 Each additional day of ICU observation or longer duration of the hospitalization increases that
cost. An investigation looking at discharge disposition after lung transplant found that increased ICU and hospital LOS were independent predictors of the need for discharge to an inpatient rehabilitation unit instead of home. 29 The findings in our investigation suggest that abstaining from alcohol while awaiting lung transplant may be one additional factor that the patient can control to stay healthy and prepared for surgery and potentially optimizing their lung transplant outcome.
It is not clear in this investigation why the patients with recent alcohol use had prolonged mechanical ventilation and LOS. Alcohol use does affect the inflammatory response and increases the risk for infections and pneumonias. 3 Our group, amongst others, has noted that in lung donors, heavy alcohol use is associated with an increased risk of PGD, an early complication following lung transplant that can increase morbidity and mortality in lung transplant recipients. 30, [32] [33] [34] However, the recent alcohol use patients did not have an increased rate of PGD, nor was there a difference in the drinking habits of their lung donors. In the recent alcohol use group, there were no observations of alcohol withdrawal causing delirium or an increase number of deaths. Certainly, the patients with recent alcohol use acquired several post-transplant complications, and perhaps their ability to recover quickly from these complications is lower. This investigation is limited by the small cohort size and the limited amount of alcohol use observed. It is reassuring that such a small portion of the cohort had evidence of alcohol use at transplant and none at levels that would be considered alcohol misuse. However, there was a significant portion of transplant recipients who either declined participation or were not approached. Additionally, there were 9 participants who had AUDITs collected without biomarkers. This increases the likelihood that drinking alcohol while awaiting lung transplant may be underrepresented in this sample. Despite this limitation, the findings of this investigation have important implications for people with advanced lung disease, in maintaining optimal health for potentially ideal outcomes after lung transplant. We are also planning a future investigation with a larger sample size.
In conclusion, the majority of patients with advanced lung dis- Further investigation in larger cohorts is necessary to fully understand the risk of alcohol use while awaiting lung transplant.
